ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Review of promising benzimidazole-based anticancer agents (2023-2026).
Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benzimidazoles represent a key class of heterocyclic compounds that stand out for their wide range of biological activity. This scaffold has become particularly important in medicinal chemistry due to its ability to mimic the purine bases of natural nucleosides, which ensures active interaction with biological targets. Today, the benzimidazole moiety provides a basis for many clinically significant drugs, such as omeprazole, albendazole, pantoprazole, and others. The potential of benzimidazole derivatives as inhibitors of cancer cell proliferation has actively been studied in recent years. In this regard, the development of highly selective, low-toxicity cytostatic molecules based on benzimidazole is highly relevant for modern oncopharmacology. This paper provides a systematic overview of advances reported over 2023-2026 in the anticancer activity of benzimidazole derivatives. The focus is on the results of preclinical studies on a panel of cell lines, including cervical carcinoma (HeLa), bladder carcinoma (HTB-9), non-small cell lung cancer (A-549), colorectal carcinoma (HCT-116), colon cancer (HT-29), chronic myeloid leukemia (K-562), acute lymphoblastic leukemia (CCRF-CEM), breast adenocarcinoma (MCF-7), triple-negative breast cancer (MDA-MB-231), hepatocellular carcinoma (HepG2), and glioblastoma (LN-18). The data analysis revealed the most promising compounds that exhibit a pronounced cytostatic activity against cancer cells. The relationship between the molecular structure and activity of the examined compounds was evaluated. This review summarizes the latest achievements in this field and can serve as a basis for a further search for novel benzimidazole skeleton-containing anticancer agents.
Indexed as
Identifiers
42627504What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.